ATLANTA, GA – – (Globe Newswire – September 12, 2023) – – Holzer & Holzer, LLC is investigating whether Acelyrin, Inc. (“Acelyrin” or “the Company”) (NASDAQ: SLRN) complied with federal securities laws.  On September 11, 2023, Acelyrin announced top-line results from a clinical trial of izokibep, revealing that the drug failed to meet the primary endpoint of showing statistically significant reduction in abscesses and inflammatory nodules compared to patients receiving a placebo. The Company attributed the results to patient discontinuations and placebo responses. Following this news, the price of the Company’s stock dropped.

If you purchased Acelyrin stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/acelyrin/ to discuss your legal rights.